Testosterone supplementation in aging men and women: possible impact on cardiovascular-renal disease

被引:77
作者
Reckelhoff, JF
Yanes, LL
Iliescu, R
Fortepiani, LA
Granger, JP
机构
[1] Univ Mississippi, Med Ctr, Dept Physiol & Biophys, Jackson, MS 39216 USA
[2] Univ Mississippi, Med Ctr, Ctr Excellence Cardiovasc Renal Res, Jackson, MS 39216 USA
关键词
androgen receptor; oxidative stress; angiotensin II; endothelin; cytokines;
D O I
10.1152/ajprenal.00034.2005
中图分类号
Q4 [生理学];
学科分类号
071003 ;
摘要
Treatment of aging men and women with testosterone supplements is increasing. The supplements are given to postmenopausal women mainly to improve their libido and to aging men to improve muscle mass and bone strength, to improve libido and quality of life, to prevent and treat osteoporosis, and, with the phosphodiesterase-5 inhibitors, such as sildenafil, to treat erectile dysfunction. The increased use of testosterone supplements in aging individuals has occurred despite the fact that there have been no rigorous clinical trials examining the effects of chronic testosterone on the cardiovascular-renal disease risk. Studies in humans and animals have suggested that androgens can increase blood pressure and compromise renal function. Androgens have been shown to increase tubular sodium and water reabsorption and activate various vasoconstrictor systems in the kidney, such as the renin-angiotensin system and endothelin. There is also evidence that androgens may increase oxidative stress. Furthermore, the kidney contains the enzymes necessary to produce androgens de novo. This review presents an overview of the data from human and animal studies in which the role of androgens in promoting renal and cardiovascular diseases has been investigated.
引用
收藏
页码:F941 / F948
页数:8
相关论文
共 87 条
[71]   Gender differences in the renal nitric oxide (NO) system - Dissociation between expression of endothelial NO synthase and renal hemodynamic response to NO synthase inhibition [J].
Reckelhoff, JF ;
Hennington, BS ;
Moore, AG ;
Blanchard, EJ ;
Cameron, J .
AMERICAN JOURNAL OF HYPERTENSION, 1998, 11 (01) :97-104
[72]   Measurement of F2-isoprostanes unveils profound oxidative stress in aged rats [J].
Roberts, LJ ;
Reckelhoff, JF .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2001, 287 (01) :254-256
[73]   ROLE OF GONADAL-HORMONES IN HYPERTENSION IN THE DAHL SALT-SENSITIVE RAT [J].
ROWLAND, NE ;
FREGLY, MJ .
CLINICAL AND EXPERIMENTAL HYPERTENSION PART A-THEORY AND PRACTICE, 1992, 14 (03) :367-375
[74]   Sexual hormone abnormalities in male patients with renal failure [J].
Schmidt, A ;
Luger, A ;
Hörl, WH .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2002, 17 (03) :368-371
[75]   Testosterone therapy in the ageing male: what about the prostate? [J].
Schultheiss, D ;
Machtens, S ;
Jonas, U .
ANDROLOGIA, 2004, 36 (06) :355-365
[76]   The role of gender in the progression of renal disease [J].
Silbiger, SR ;
Neugarten, J .
ADVANCES IN RENAL REPLACEMENT THERAPY, 2003, 10 (01) :3-14
[77]  
Sluijmer AV, 1998, MENOPAUSE, V5, P207
[78]   Physiology and pathology of endothelin-1 in renal mesangium [J].
Sorokin, A ;
Kohan, DE .
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 2003, 285 (04) :F579-F589
[79]   Intrinsa fails to impress FDA advisory panel [J].
Spark, RF .
INTERNATIONAL JOURNAL OF IMPOTENCE RESEARCH, 2005, 17 (03) :283-284
[80]   Risk factors for renal cysts [J].
Terada, N ;
Arai, Y ;
Kinukawa, N ;
Yoshimura, K ;
Terai, A .
BJU INTERNATIONAL, 2004, 93 (09) :1300-1302